Looking at the biotech sector right now, new drug approvals could gain momentum in the wake of the FDA’s approval of Biogen’s Alzheimer’s drug, mergers… Read More »3 Outperforming Biotech Stocks With Further Upside In The Back Half Of 2021
The five biotech stocks discussed in today’s article were among the worst performers in the first half of 2021 – but thanks to upcoming catalysts,… Read More »Thanks To Upcoming Catalysts, These Biotech Stocks Could Go From First-Half Losers To Second-Half Winners
When it comes to the race for COVID-19 vaccines that captured the attention of biotech investors last year, the author of today’s article notes that… Read More »3 Biotech Stocks Poised For Growth Unrelated To COVID-19
A clinical-stage biopharmaceutical company focused on the development of novel therapeutics and delivery methods for breast cancer and other breast conditions, as well as three… Read More »4 Biotech Stocks To Watch Heading Into July
“Five stocks for aggressive accounts that look to get share-count leverage on companies that have sizable upside potential” is what today’s article highlights – and… Read More »“Sizable Upside Potential”: 5 Smaller Cap Stocks For More Aggressive Investors
When it comes to stock selection, avoiding losers is just as important – and maybe even more important – than picking winners. This is why… Read More »A Biotech Play “On The Right Side Of Volatility”
In the wake of the company disclosing in May that it would be delaying its Biologic License Application filing with the FDA for its key… Read More »Is The Sell-Off In This Biotech Stock A Buying Opportunity? Cathie Wood Thinks So.
Even as many big names in biotech perform well, the author of today’s article notes that “penny biotech stocks, mostly small firms working on only… Read More »Selecting The Best Biotech Penny Stocks
The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm resulted in shares of the biotech rocketing higher – and the rest of the biotech sector went… Read More »Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
The biotech featured in today’s article, focused on a new scientific approach to tackling Alzheimer’s disease and other neurodegenerative disorders, is up 884% so far… Read More »A Promising Drug Candidate For Both Alzheimer’s And Parkinson’s Disease Could Drive This Surging Biotech Even Higher